Inovio Pharmaceuticals Investors Urged to Join Fraud Class Action for Potential Compensation
Inovio Pharmaceuticals, Inc. has recently come under scrutiny as investors holding shares between October 10, 2023, and December 26, 2025, are being called to action regarding a class action lawsuit that alleges significant securities fraud. The Rosen Law Firm, a prominent legal entity specializing in investor rights, has announced a lead plaintiff deadline for potential claimants, emphasizing the urgency for stakeholders who may have incurred losses exceeding $100,000 during the specified class period.
The lawsuit revolves around accusations that Inovio's management provided false and misleading statements concerning their CELLECTRA device and other aspects of the company, which misrepresented the viability and regulatory prospects of their INO-3107 product. Claims include assertions that manufacturing deficiencies may lead to the inability of Inovio to submit a pivotal Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) by the expected timeframe, alongside overstated commercial prospects of their innovations.
The Rosen Law Firm has urged affected investors to step forward and consider participating in the class action, stating that they could be entitled to compensation without bearing any immediate out-of-pocket expenses, thanks to a contingency fee arrangement. To register, potential plaintiffs are directed to fill out an online form available on the firm’s website or contact an attorney directly for more information.
Furthermore, investors are reminded that, while a class action is already underway, certification has not yet been granted. Therefore, affected individuals are not legally represented unless they choose to retain counsel. This situation presents an opportunity for investors to potentially act as lead plaintiffs, which involves directing the lawsuit on behalf of other affected shareholders.
The lawsuit revolves around accusations that Inovio's management provided false and misleading statements concerning their CELLECTRA device and other aspects of the company, which misrepresented the viability and regulatory prospects of their INO-3107 product. Claims include assertions that manufacturing deficiencies may lead to the inability of Inovio to submit a pivotal Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) by the expected timeframe, alongside overstated commercial prospects of their innovations.
The Rosen Law Firm has urged affected investors to step forward and consider participating in the class action, stating that they could be entitled to compensation without bearing any immediate out-of-pocket expenses, thanks to a contingency fee arrangement. To register, potential plaintiffs are directed to fill out an online form available on the firm’s website or contact an attorney directly for more information.
Furthermore, investors are reminded that, while a class action is already underway, certification has not yet been granted. Therefore, affected individuals are not legally represented unless they choose to retain counsel. This situation presents an opportunity for investors to potentially act as lead plaintiffs, which involves directing the lawsuit on behalf of other affected shareholders.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.